adjusted (20) cut-points both result in NPV 90, with sensitivity of 94% and 92%, respectively. The number of avoided biopsies is greater (30%) with the adjusted cut-point of 20 vs. the original validated cutpoint (21%); while missing only 1>/¼ISUP 3 case. The original validated cut-point would have avoided biopsies in 30% of men with GS6 or benign disease while the adjusted cut-point would have avoided 43% of biopsies in this population.
INTRODUCTION AND OBJECTIVES: Axitinib is a potent oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) not previously tested in the UK in metastatic RCC patients with their primary tumour in situ. A-PREDICT aims to determine whether axitinib has activity in this population and explore biomarkers of activity and resistance METHODS: A-PREDICT is a phase II single group study (maximum n¼99) of axitinib (starting dose 5mg BID) in patients with metastatic clear cell RCC unable to have immediate cytoreductive nephrectomy. Participants consented to provide biosamples (tumour, blood, urine) at baseline, on treatment and at progression. The primary endpoint is proportion of patients alive and free from disease progression (RECIST v1.1) at 6 months. Secondary endpoints include toxicity (CTCAE v4), progression free, overall survival and correlation of biomarkers with clinical endpoints.
RESULTS: 65 participants were recruited between 10/10/2012 and 23/12/2016. In December 2016 the Independent Data Monitoring and Steering Committee recommended that the trial close to recruitment as the pre-defined threshold level of activity had been reached. As of 19/12/2016 tumour samples were available for 92% participants at baseline, 87% on treatment and 13% at progression with equivalent return rates for blood and for urine samples. Final data on response and toxicity will be available Q2 2017.
CONCLUSIONS: Recruitment to translational studies is challenging. Due to close cooperation of oncologists, urologists, radiologists and pathologists, A-PREDICT represents the largest UK translational therapeutic study of first line treatment using axitinib in metastatic RCC, presenting a unique opportunity to study mechanisms of sensitivity and resistance to axitinib. Importantly, axitinib met predefined activity thresholds.
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PNFLBA-17 DETECTION OF CIRCULATING TUMOR CELL IN THE PATIENTS WITH PROSTATE CANCER USING NOVEL VIRAL MARKER OBP-1101
Nobuyuki Hinata*, Yukari Bando, Akira Miyazaki, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Masato Fujisawa, Kobe, Japan INTRODUCTION AND OBJECTIVES: Circulating tumor cell (CTC) is reported in several studies as a promising predictor of survival or treatment response. However, CTC detection by using immunohistochemical techniques some limitations, such as dead cancer cells could be detected, insufficient sensitivity, or inability to detect epithelialmesenchymal transformation (EMT). OBP-1101 is a novel adenovirusderived detection marker for cancer cells. Green Fluorescent Protein (GFP) protein gene expression is controlled by telomerase promoter in OBP-1101 and might be resolve above-mentioned problems.
METHODS: After IRB approval, 15 ml blood samples were collected from 49 patients with prostate cancer at Kobe University Hospital. Detection of CTC using OBP-1011 was performed and these results were compared with patient demographics. Clinical stage, Gleason score, PSA, NCCN risk classification were analyzed whether they correlate with GFP positivities. In addition, results of immunohistochemical staining using EpCAM antibody and PSMA antibody were compared with GFP positivities.
RESULTS: GFP positive CTC was detected in 26 cases (53.1%). EpCAM positive CTC was detected in 28 cases (57.1%). Among 28 EpCAM positive cases, PSMA positive CTCs were detected in 25 cases (89.3%). On the other hand, PSMA positive CTCs were detected only in 4 cases (8.2%). None of the Clinical stage, Gleason score, PSA, risk classification correlated with GFP positivity or EpCAM positivity.
CONCLUSIONS: The CTCs detected by using OBP-1101 could have different characteristics from those detected by using epithelial markers. These characteristics to detect EMT might be markers of worse clinical outcomes and change clinical decision making. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e917
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